You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Countdown to Clinical Knowledge of IL-17 Inhibitors in Psoriasis

  • Authors: Ulrich Mrowietz, MD; Laura Savage, MD
  • CPD Released: 9/16/2021
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 9/16/2022
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US dermatologists, pediatricians, and primary care physicians.

The goal of this activity is to relate data on interleukin (IL)-17 inhibitors to clinical practice and address broader issues in psoriasis (PsO) management, such as treatment goals and recommendations.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Benefit/risk profile for IL-17 inhibitors in PsO 
    • Key quality of life data for IL-17 inhibitors in psoriasis 


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Moderator

  • Ulrich Mrowietz, MD

    Professor of Dermatology
    University Medical Center Schleswig-Holstein
    Kiel Campus, Germany

    Disclosures

    Disclosure: Ulrich Mrowietz, MD, has the following relevant financial relationships:
    Advisor or consultant for: AbbVie; Aditxt; Almirall; Amgen; Aristea; Boehringer Ingelheim; Bristol Myers Squibb Company; Celgene; Dr. Reddy’s; Foamix; Formycon; Immunic; Janssen; LEO Pharma; Lilly; Medac; Novartis; Phi-Stone; Pierre Fabre; Sanofi-Aventis; UCB
    Speaker or a member of a speakers bureau for: AbbVie; Almirall; Amgen; Boehringer Ingelheim; Celgene; Foamix; Janssen; LEO Pharma; Lilly; Medac; Novartis; Sanofi-Aventis; UCB
    Grants for clinical research from: AbbVie; Almirall; Celgene; Janssen; Novartis; UCB

Faculty

  • Laura Savage, MD

    Consultant Dermatologist
    Leeds Centre for Dermatology
    Honorary Senior Lecturer
    University of Leeds
    United Kingdom

    Disclosures

    Disclosure: Laura Savage, MD, has the following relevant financial relationships:
    Advisor or consultant for: AbbVie; Almirall; Amgen; Biogen; Celgene; Janssen; LEO Pharma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; UCB
    Speaker or a member of a speakers bureau for: AbbVie; Almirall; Amgen; Biogen; Celgene; Janssen; LEO Pharma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; UCB
    Grants for clinical research from: Janssen; Pfizer

Editors

  • Alessia Piazza, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Alessia Piazza, PhD, has disclosed no relevant financial relationships.

  • Eloise Ballard, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Disclosure: Eloise Ballard, PhD, has disclosed no relevant financial relationships.

Content Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Countdown to Clinical Knowledge of IL-17 Inhibitors in Psoriasis

Authors: Ulrich Mrowietz, MD; Laura Savage, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 9/16/2021

Valid for credit through: 9/16/2022

processing....

Deutscher Expertenkommentar

Dieser Kommentar ist Teil einer umfangreicheren Fortbildungsmaßnahme. Kehren Sie für den Zugriff auf alle zugehörigen Fortbildungsinhalte nach Ihrer Teilnahme bitte zurück zu   Countdown to Clinical Knowledge of IL-17 Inhibitors in Psoriasis .

« Return to: Countdown to Clinical Knowledge of IL-17 Inhibitors in Psoriasis
  • Print